IMMUNOGENICITY AND SAFETY STUDY OF GSK BIOLOGICALS' CANDIDATE MALARIA VACCINE GIVEN AT 6, 7.5 AND 9 MONTHS OF AGE IN CO-ADMINISTRATION WITH MEASLES, RUBELLA AND YELLOW FEVER (YF) VACCINES FOLLOWED BY A BOOSTER OF THE MALARIA VACCINE.: